DDInter712 DDInter1676
Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Famotidine {u} (Compound) binds {v} (Gene) SLC47A1
Famotidine {u} (Compound) upregulates {v} (Gene) IFNAR1
Famotidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Famotidine {u} (Compound) downregulates {v} (Gene) PCNA
Famotidine {u} (Compound) causes {v} (Side Effect) Jaundice
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Famotidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Famotidine (Compound) binds SLC47A1 (Gene)
Famotidine (Compound) upregulates IFNAR1 (Gene)
Famotidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Famotidine (Compound) downregulates PCNA (Gene)
Famotidine (Compound) causes Jaundice (Side Effect)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Famotidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine
Famotidine may lead to a major life threatening interaction when taken with Dasatinib